Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue npj Parkinson's Disease Année : 2023

Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers

Jean-Marc Taymans
Eugénie Mutez
William Sibran
  • Fonction : Auteur
Laurine Vandewynckel
  • Fonction : Auteur
Claire Deldycke
  • Fonction : Auteur
Séverine Bleuse
  • Fonction : Auteur
Antoine Marchand
Alessia Sarchione
  • Fonction : Auteur
Coline Leghay
  • Fonction : Auteur
Alexandre Kreisler
  • Fonction : Auteur
Clémence Simonin
  • Fonction : Auteur
James Koprich
  • Fonction : Auteur
Guillaume Baille
  • Fonction : Auteur
Luc Defebvre
  • Fonction : Auteur
Kathy Dujardin
Alain Destée
  • Fonction : Auteur
Marie-Christine Chartier-Harlin

Résumé

Abstract Expression or phosphorylation levels of leucine-rich repeat kinase 2 (LRRK2) and its Rab substrates have strong potential as disease or pharmacodynamic biomarkers. The main objective of this study is therefore to assess the LRRK2-Rab pathway for use as biomarkers in human, non-human primate (NHP) and rat urine. With urine collected from human subjects and animals, we applied an ultracentrifugation based fractionation protocol to isolate small urinary extracellular vesicles (uEVs). We used western blot with antibodies directed against total and phosphorylated LRRK2, Rab8, and Rab10 to measure these LRRK2 and Rab epitopes in uEVs. We confirm the presence of LRRK2 and Rab8/10 in human and NHP uEVs, including total LRRK2 as well as phospho-LRRK2, phospho-Rab8 and phospho-Rab10. We also confirm LRRK2 and Rab expression in rodent uEVs. We quantified LRRK2 and Rab epitopes in human cohorts and found in a first cohort that pS1292-LRRK2 levels were elevated in individuals carrying the LRRK2 G2019S mutation, without significant differences between healthy and PD groups, whether for LRRK2 G2019S carriers or not. In a second cohort, we found that PD was associated to increased Rab8 levels and decreased pS910-LRRK2 and pS935-LRRK2. In animals, acute treatment with LRRK2 kinase inhibitors led to decreased pT73-Rab10. The identification of changes in Rab8 and LRRK2 phosphorylation at S910 and S935 heterologous phosphosites in uEVs of PD patients and pT73-Rab10 in inhibitor-dosed animals further reinforces the potential of the LRRK2-Rab pathway as a source of PD and pharmacodynamic biomarkers in uEVs.
Fichier principal
Vignette du fichier
s41531-023-00445-9.pdf (1.71 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04335821 , version 1 (12-02-2024)

Identifiants

Citer

Jean-Marc Taymans, Eugénie Mutez, William Sibran, Laurine Vandewynckel, Claire Deldycke, et al.. Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers. npj Parkinson's Disease, 2023, 9 (1), pp.21. ⟨10.1038/s41531-023-00445-9⟩. ⟨hal-04335821⟩

Collections

UNIV-LILLE
8 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More